Total Payments
$49,937
2024 Payments
$32,508
Companies
34
Transactions
525
Medicare Patients
9,529
Medicare Billing
$690,277
Payment Breakdown by Category
Other$36,450 (73.0%)
Food & Beverage$12,834 (25.7%)
Travel$415.55 (0.8%)
Consulting$200.00 (0.4%)
Education$37.94 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,450 | 25 | 73.0% |
| Food and Beverage | $12,834 | 489 | 25.7% |
| Travel and Lodging | $415.55 | 7 | 0.8% |
| Consulting Fee | $200.00 | 1 | 0.4% |
| Education | $37.94 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $39,798 | 119 | $0 (2024) |
| GENZYME CORPORATION | $1,675 | 27 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,306 | 80 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $715.31 | 25 | $0 (2024) |
| Insmed, Inc. | $666.33 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $590.84 | 16 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $580.22 | 18 | $0 (2024) |
| United Therapeutics Corporation | $549.79 | 18 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $490.48 | 26 | $0 (2024) |
| Electromed, Inc. | $464.38 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,508 | 191 | AstraZeneca Pharmaceuticals LP ($29,388) |
| 2023 | $4,027 | 133 | AstraZeneca Pharmaceuticals LP ($1,080) |
| 2022 | $10,239 | 74 | AstraZeneca Pharmaceuticals LP ($8,729) |
| 2021 | $1,652 | 80 | AstraZeneca Pharmaceuticals LP ($430.72) |
| 2020 | $290.39 | 17 | Insmed, Inc. ($122.62) |
| 2019 | $618.74 | 9 | Genentech USA, Inc. ($127.77) |
| 2018 | $265.00 | 6 | Novartis Pharmaceuticals Corporation ($115.15) |
| 2017 | $337.28 | 15 | Novartis Pharmaceuticals Corporation ($112.23) |
All Payment Transactions
525 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $33.14 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.33 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $121.72 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $17.51 | General |
| Category: HFCWO | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/10/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $25.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: Immunology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $21.34 | General |
| Category: HFCWO | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $0.70 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: RESPIRATORY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Cardiology | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: RESPIRATORY | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,211 | 3,596 | $422,845 | $164,159 |
| 2022 | 19 | 2,234 | 3,663 | $426,650 | $160,216 |
| 2021 | 20 | 2,568 | 4,063 | $472,376 | $175,950 |
| 2020 | 23 | 2,516 | 4,109 | $557,190 | $189,952 |
Total Patients
9,529
Total Services
15,431
Medicare Billing
$690,277
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 566 | 1,162 | $169,344 | $72,137 | 42.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 220 | $47,260 | $20,140 | 42.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 68 | 244 | $36,356 | $14,838 | 40.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 70 | 364 | $30,432 | $13,804 | 45.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 97 | $20,331 | $8,407 | 41.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 64 | 64 | $20,160 | $7,798 | 38.7% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 502 | 588 | $17,640 | $3,532 | 20.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 42 | 42 | $8,658 | $3,313 | 38.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $8,587 | $3,111 | 36.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $8,547 | $2,813 | 32.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 38 | 38 | $7,030 | $2,733 | 38.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 15 | $8,475 | $2,346 | 27.7% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 141 | 175 | $10,500 | $2,335 | 22.2% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 21 | 21 | $12,474 | $1,832 | 14.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 167 | 168 | $5,712 | $1,492 | 26.1% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 205 | 206 | $5,356 | $1,365 | 25.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 41 | 41 | $1,435 | $1,186 | 82.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 50 | 50 | $2,400 | $374.51 | 15.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 17 | 18 | $990.00 | $307.98 | 31.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 16 | $768.00 | $163.04 | 21.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 13 | 15 | $390.00 | $131.81 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 575 | 1,131 | $162,864 | $68,495 | 42.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 49 | 216 | $46,224 | $17,139 | 37.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 75 | 310 | $46,190 | $16,782 | 36.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 84 | 426 | $35,358 | $12,412 | 35.1% |
About Dr. Mark Mayson, MD
Dr. Mark Mayson, MD is a Pulmonary Disease healthcare provider based in Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962480889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mayson, MD has received a total of $49,937 in payments from pharmaceutical and medical device companies, with $32,508 received in 2024. These payments were reported across 525 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($36,450).
As a Medicare-enrolled provider, Mayson has provided services to 9,529 Medicare beneficiaries, totaling 15,431 services with total Medicare billing of $690,277. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Columbia, SC
- Active Since 01/03/2006
- Last Updated 02/19/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1962480889
Products in Payments
- AIRSUPRA (Drug) $26,160
- FASENRA (Biological) $12,374
- DUPIXENT (Biological) $2,015
- TRELEGY ELLIPTA (Drug) $752.09
- Arikayce (Drug) $586.30
- TYVASO (Drug) $485.77
- XOLAIR (Biological) $473.90
- NUCALA (Biological) $472.67
- SMARTVEST (Device) $464.38
- GLASSIA (Biological) $449.46
- UPTRAVI (Drug) $419.54
- OFEV (Drug) $382.17
- TEZSPIRE (Biological) $344.31
- DIFICID (Drug) $232.82
- Adempas (Drug) $200.00
- OPSUMIT (Drug) $169.08
- BREZTRI (Drug) $160.62
- Actemra (Biological) $150.00
- YUPELRI (Drug) $135.48
- FASENRA (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Columbia
Dr. Richard Bogan, M.d, M.D
Pulmonary Disease — Payments: $1.2M
Pulmonary Disease $1.2M
Dr. Laura Herpel, M.d, M.D
Pulmonary Disease — Payments: $144,324
Pulmonary Disease $144,324
Dr. Carlton Cauthen, M.d, M.D
Pulmonary Disease — Payments: $116,511
Pulmonary Disease $116,511
Edward Schaefer, Md, MD
Pulmonary Disease — Payments: $16,280
Pulmonary Disease $16,280
Jason Goodin, D.o, D.O
Pulmonary Disease — Payments: $14,722
Pulmonary Disease $14,722
Yuji Oba, M.d, M.D
Pulmonary Disease — Payments: $14,418
Pulmonary Disease $14,418